Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report

J Dermatol. 2020 Jan;47(1):e9-e11. doi: 10.1111/1346-8138.15140. Epub 2019 Oct 31.

Authors

Yusuke Muto¹, Kenjiro Namikawa¹, Yutaka Fujiwara², Taisuke Mori³, Eiji Nakano¹, Akira Takahashi¹, Naoya Yamazaki¹

Affiliations

¹ Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
³ Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.

PMID: 31674068
DOI: 10.1111/1346-8138.15140

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Glucocorticoids / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Male
Pemphigoid, Bullous / chemically induced
Pemphigoid, Bullous / drug therapy*
Remission Induction
Withholding Treatment

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Glucocorticoids
pembrolizumab